Merz Therapeutics is a specialty neurology biopharma focused on movement disorders, rare and ophan neurological diseases and chronic pain seeking in-licensing and acquisition opportunities. Areas of highest interest include Multiple Sclerosis, Parkinson’s Disease and other diseases characterized by motor dysfunction such as dystonia, spasticity, blepharospasms;, Ataxia Rare and orphan neurological disorders including hereditary neuropathies and neurodegenerative diseases, ideally with movement disorder aspects Migraine and chronic pain, e.g. neuropathic pain We look forward to discuss strategic partnerships/in-licensing/M&A for patent protected commercial and development stage assets in Phase 2 or later.